Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (March 2015)
28 slides from Elron Ventures's investor presentation, Mar 12, 2015
Slide 1: Form 6-K Elron Electronic Industries Ltd.
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of March 2015 ELRON ELECTRONIC INDUSTRIES LTD. (Translation of Registrant’s Name into English) 3Azrieli Center, Triangle
Slide 2: English Translation of Registrant's Investors' Presentation
English Translation of Registrant's Investors' Presentation filed with the Israeli Securities Authority. 2
Slide 3: Signature
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ELRON ELECTRONIC INDUSTRIES LTD. (Registrant) By: /s/ Yaron Elad Yaron Elad VP & CFO Dated: March 12, 20
Slide 4: Discover. Innovation - March 2015
DISCOVER. INNOVATION March 2015
Slide 5: Disclaimer
This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the features or content presented
Slide 6: Elron. Seeking to change the face of healthcare
ELRON. SEEKING TO CHANGE THE FACE OF HEALTHCARE
Slide 7: Operational holding company and portfolio overview
§ Operational holding company BRAINSGATE STROKE CARE 30% § A portfolio of companies with significant exit potential POCARED § Continuing to examine new MICROBIOLOGY 53% investments in cutting-edge med-tech technologies NOTAL AMD VISION 21% § Financial results 2014: § $85.5m: profit CARTIHEAL § $287.
Slide 8: Aggregate value of exits ~$1.4b
§ Aggregate value of exits: ~$1.4b § Elron’s and RDC’s total exit proceeds (after tax): ~$573m § ~$200m invested in med-tech companies in recent years 5
Slide 9: 4 out of the last 5 years were profitable
§ 4 out of the last 5 years were profitable 6
Slide 10: 2014 positive cash flow and dividend distributed
§ 2014: positive cash flow of ~$184m § $110m dividend distributed in 2014 § $15m dividend distributed in 2012 § No debt 7
Slide 11: The case of RDC: partnership with Rafael
THE CASE OF RDC: PARTNERSHIP WITH § Exclusive rights to RAFAEL commercialize Rafael’s military + jointly held by Elron (50.1%) and Rafael (49.9%) technologies in civilian markets + Rafael: Israeli provider of defense systems with $2b in annual sales § The Rafael-Elron agreement is exclusive and inde
Slide 12: Elron. Promise
ELRON. PROMIS
Slide 13: BrainsGate: treatment of ischemic stroke
Elron’s holding: 30% Founded: 2000 Treatment of ischemic stroke in a 24 hour window post symptom onset First investment: 2005 Total investment: $81m ($25m Current treatment (tPA protein) is approved for use during a by Elron) 3-4.5 hour window only Main partners: Johnson & Johnson, Boston Scientific
Slide 14: BrainsGate FDA trial and stroke market
$95b is the estimated cost of stroke in the U.S. projected for In 2010 BrainsGate completed a clinical trial on 300 patients 2015 with results that strengthened the assessment that the 15m people suffer a stroke treatment is effective and safe worldwide each year 5% of stroke victims receive BrainsG
Slide 15: BrainsGate treatment vs. current treatment
Restores blood flow to the Electrical stimulation induces blocked blood vessel dilation of cerebral blood vessels, and thus augments Due to the temporary blood flow interruption in blood flow, the blood vessel becomes The stimulation avoids brittle manipulating the blood clot, and treats only surrou
Slide 16: Pocared: infectious disease diagnosis system
Elron’s holding: 53% Founded: 2004 Real-time and automated system for infectious disease diagnosis, based on optical technology First investment: 2007 Total investment: $82m ($42m Designed for use by major microbiological laboratories by Elron) and hospitals Main partner: SCP Vitalife Meant to repla
Slide 17: Pocared FDA trial and urine culture market
125m urine cultures are performed each year in the U.S. The system is CE certified since December 2011 70% of urine cultures return negative, after antibiotics have Pocared is currently conducting a trial to test the efficacy of the been unnecessarily administered system's 1st application, UTI diagn
Slide 18: Elron. Innovation
ELRON. INNOVATION FROM 48 HRS TO 48 MIN a complete cartridge transfer carousel to carousel optical analyzer module urine sample cartridge results...
Slide 19: Notal Vision: remote monitoring of AMD
Elron’s holding: 21% Founded: 2000 Remote monitoring of patients at risk of vision loss from AMD First investment: 2003 Total investment: $37m ($8.5m AMD destroys sharp, central vision, necessary for common by Elron) tasks such as facial recognition, driving, reading, & Main partners: Evergreen, wat
Slide 20: Notal Vision Medicare coverage decision expected 2015
AMD is the leading cause of severe vision loss and blindness in Notal Vision began marketing the ForeseeHome in the U.S. adults over age 50 in the western world The American Academy of Ophthalmology (AAO) adopted a ~9.1m individuals with dry AMD recommendation in its clinical guidelines for early de
Slide 21: The device detects even small changes in vision
The device detects even The Data Monitoring Center small changes in vision alerts patient & doctor 18 Notal Vision website: http://www.notalvision.com/
Slide 22: Cartiheal: implant for cartilage repair
Elron’s holding: 33% Founded: 2009 Implant for repairing cartilage and osteochondral defects in loadbearing joints, such as the knee First investment: 2012 Total investment: $16m ($6.3m The implant has a unique structure, comprising of marine by Elron) aragonite with biological modifications Main pa
Slide 23: Cartiheal expanding use to knee osteoarthritis
Between 2004 and 2011 ~2m people in the U.S. have The implant is CE certified since April 2011 undergone a surgical procedure to repair cartilage in the knee Preclinical studies demonstrated cartilage & bone regeneration at the implantation site A series of clinical trials are underway at well-known
Slide 24: Post-op results: 1 day and 6 months
1 day post-op: 6 months post-op: 21
Slide 25: Holdings, book value, cash and market value
§ Book value of associates & Holdings in companies 1 Book value at Amount consolidated companies: Dec. 31, 2014 ($m) invested generally represents the ($m) amount invested in the Associates and consolidated companies less our share in Pocared 2 companies: 6.1 41.8 BrainsGate 2 2.3 24.5 their losses,
Slide 26: Investment highlights
Proven expertise in identifying opportunities, building technology leaders, and exiting holdings Operational holding company with the ability to provide its group companies long-term commitment Strategic partnership with Rafael - access to state-of-the-art military technologies, and exclusive rights
Slide 27: Quote from Elron's founder Uzia Galil
“ Looking ahead, Elron should always understand that the ever evolving changes in the high tech industry will be exponential, and therefore, success will depend on choosing the right niches in the world market in which it can maintain and improve its relative advantage. Mr. Uzia Galil, Elron’s found
Slide 28: Elron. Opportunity - Thank you
ELRON. OPPORTUNITY Thank you.
Elron Electronic Industries — Investor Presentation (March 2015) on 6ix